Plasma myostatin measured by a competitive ELISA using a highly specific antiserum

Area of Science:

• Biochemistry
• Physiology
• Immunology

Background:

• Myostatin (Myo) is a key regulator of skeletal muscle mass.
• Understanding Myo's role is vital for skeletal muscle disorders and cardiac disease.
• A reliable assay for plasma Myo immunoreactivity is currently unavailable.

Purpose of the Study:

• To develop and validate the first enzyme-linked immunosorbent assay (ELISA) for measuring myostatin immunoreactivity in human plasma.
• To assess the utility of this assay in patients with congestive heart failure (CHF).

Main Methods:

• A polyclonal rabbit antiserum was generated using human full-length proMyo.
• A competitive Myo ELISA was developed and validated.
• The assay was tested in patients with decompensated CHF and control subjects.

Main Results:

• The developed ELISA demonstrated high specificity, with no cross-reactivity to related proteins.
• The assay exhibited good linearity, low variance (inter-assay ≤15%, intra-assay ≤10%), and a sensitive detection limit (270 pg/ml).
• Plasma Myo levels were significantly elevated in decompensated CHF patients and decreased upon successful therapy.

Conclusions:

• The study presents the first validated ELISA for myostatin immunoreactivity.
• This assay is a valuable tool for studying neurological and cardiac diseases.
• The assay can also aid in investigating conditions like cachexia, insulin resistance, and obesity.